期刊文献+

miR-134 miR-17~92基因簇与卵巢癌耐药的关系 被引量:2

Differentially expressions of miR-134 and miR-17-92 clusters and ovarian cancer paclitaxel resistance
原文传递
导出
摘要 目的检测并验证miR-134及miR-17~92基因簇在紫杉醇耐药与敏感卵巢癌细胞中的差异表达并探讨两者参与卵巢癌耐药的可能机制。方法2010年10月至2012年12月于中国医科大学附属盛京医院,用Affymetrix GeneChip miRNA芯片对紫杉醇耐药与敏感卵巢癌细胞miRNA基因表达谱进行分析。选取差异表达明显的miR-134和miR-17~92基因簇,采用Real-timePCR方法进一步验证芯片结果。应用生物信息学分析软件预测miR-134和miR-17~92基因簇各自潜在的靶基因并通过WesternBlot对部分靶基因进行验证。结果与敏感卵巢癌SKOV3细胞相比,耐药卵巢癌SKOV3-TR30细胞中miR-134低表达,miR-17~92基因簇高表达。软件预测得到miR-134基因簇潜在靶基因c-Myc,MRP1/ABCCl等共128个,软件预测得到miR-17~92基因簇潜在靶基因BIM,PTEN,ABCAl等共30个。与敏感卵巢癌SKOV3细胞相比,耐药卵巢癌SKOV3-TR30细胞中miR-134潜在靶基因c-Myc蛋白高表达;miR-17~92基因簇潜在靶基因BIM蛋白低表达(P均〈0.05),PTEN蛋白虽表达增高但差异无统计学意义。结论MicroRNA表达谱基因芯片可筛查出紫杉醇耐药与敏感卵巢癌细胞的差异表达基因。低表达miR-134和高表达的miR-17~92基因簇可能分别通过调节其潜在靶基因c-Myc及BIM蛋白表达参与卵巢癌化疗耐药。 Objective To detect the differentially miRNA expression in paclitaxel sensitive and chemoresistant ovarian cancer cell lines, and to explore the molecular mechanism of drug resistance of ovarian cancer. Methods The expression profile of miRNA were detected with miRNA microarray chip hybridization and the compared array results were further validated by Real-time PCR and Western Blot. Potential miRNA targets were predicted by bioinformatic software. Results Compared with SKOV3 cell line, miR17 -92 gene cluster with high expression while miRNA134 cluster with low expression was found in SKOV3-TR30 cells. It can be predicted by bioinformatic software that miR17 -92 gene cluster has 30 target genes such as BIM,PTEN,ABCA1 ,C10orf46,CD4, while miRNA134 cluster has 128 target genes such as MRP1/ABCC1. Western Blot showed that compared with SKOV3 ceils, BIM expression was decreased in SKOV3- TR30 cells,while c-Myc was in high expression in SKOV3-TR30 cells. Conclusion The differentially miRNA expression profiles in SKOV3 and SKOV3-TR30 can be obtained by miRNA microarray chip technology. MiR-17 -92 cluster and miR-134 cluster may be involved in drug resistance of ovarian cancer by regulating their target genes,which provide a theoretical basis for the study of ovarian cancer chemoresistance.
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2014年第2期118-122,共5页 Chinese Journal of Practical Gynecology and Obstetrics
基金 国家自然科学基金(30973189) 辽宁省自然科学基金(2013021040)
关键词 miRNA表达谱基因芯片 卵巢癌 耐药 miR-17~92 miR-134 miRNA microarray chip ovarian cancer chemoresistance miR-17 - 92 miR-134
  • 相关文献

参考文献3

二级参考文献40

  • 1Sorrentino A,Liu CG,Addario A,et al.Role of mi- croRNAs in drug-resistant ovarian cancer cells. Gynecologic Oncology . 2008
  • 2van Jaarsveld MT,Helleman J,Berns EM,et al.Mi- croRNAs in ovarian cancer biology and therapy resis- tance. International Journal of Biochemistry Cell Biology The . 2010
  • 3Ma J,Dong C,Ji C.MicroRNA and drug resistance. Cancer Gene Therapy . 2010
  • 4Jones NA,Turner J,McIlwrath AJ,et al.Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Molecular Pharmacology . 1998
  • 5Legge F,Ferrandina G,Salutari V,et al.Biological char- acterization of ovarian cancer: prognostic and therapeutic implications. Annals of Oncology . 2005
  • 6Reed NS,Sadozye AH.Role of chemotherapy in the management of epithelial ovarian cancer. Expert Review of Anticancer Therapy . 2005
  • 7Ferrandina,G.et al.Class Ⅲ beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clinical Cancer Research . 2006
  • 8Zheng T,Wang J,Chen X,Liu L.Role of microRNA in anticancer drug resistance. International Journal of Cancer . 2010
  • 9Yang H,Kong W,He L, etal.MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Research . 2008
  • 10Kobayashi T,Lu J,Cobb BS,Rodda SJ,McMahon AP,Schipani E, et al.Dicer-dependent pathways regulate chondrocyte proliferation and differentiation. Proceedings of the National Academy of Sciences of the United States of America . 2008

共引文献34

同被引文献33

  • 1王其,陈孝平,张万广,张必翔.人肝癌HepG2多药耐药细胞系的部分生物学性状研究[J].中华实验外科杂志,2004,21(5):538-540. 被引量:40
  • 2赵亚宁,李强.前凋亡蛋白Bim研究进展[J].国际输血及血液学杂志,2006,29(1):33-36. 被引量:2
  • 3P6rez-Tomfis R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment [J]. Curt Med Chem, 2006, 13(16): 1859-76.
  • 4Barancik M, Bohicovi V, Kvackajovl J, et al. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P- glycoprotein-mediated multidrug resistance [J]. Eur J Pharm Sci, 2001, 14(1): 29-36.
  • 5Wang X, Toumier C. Regulation of cellular functions by the ERK5 signalling pathway[J]. Cell Signal, 2006, 18(6): 753-60.
  • 6Snow K, Judd W. Characterisation of adriamycin- and amsacrine- resistant human leukaemie T cell lines[J]. Br J Cancer, 1991, 63(1): 17-28.
  • 7Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy[J]. Ann Med, 2006, 38(3): 200-11.
  • 8Kisuckfi J, Barancik M, Bohficovfi V, et al. Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells[J]. Gen Physiol Biophys, 2001, 20(4): 439-44.
  • 9Lochhead PA, Gilley R, Cook SJ. ERK5 and its role in tumour development[ J]. Biochem Soc Trans, 2012, 40(1 ): 251-6.
  • 10Drew BA, Burow ME, Beckman BS. MEK5/ERK5 pathway: the first fifteen years[J]. Biochim Biophys Acta, 2012, 1825(1): 37-48.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部